Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Amgen (AMGN) to $372 from $335 and keeps an Outperform rating on the shares.

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into ...

AbbVie, Amgen, and IBM are among 2025’s top dividend performers, each up more than 30% while offering solid yields and steady ...

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means ...

Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...

After showing a lack of direction early in the session, stocks moved mostly higher over the course of the trading day on Wednesday. While the Nasdaq and the S&P 500 posted ...